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Özet
Amaç: Mide kanseri birçok ülkede insidansı azalmakla birlikte dünya gene-
linde sık görülen kanserlerden biri olmaya devam etmektedir. Mide kanse-
ri, birçok genetik ve epigenetik değişiklikleri içeren biyolojik olarak hetero-
jen bir hastalıktır. Hastalığın bu heterojenitesine rağmen aynı evredeki has-
talar benzer tedavileri almakta idi. HER 2 ekspresyonun immünohistokimya-
sal olarak veya florasan in situ hibridizasyon ile gösterildiği metastatik mide 
kanserli hastalarda transtuzumab’ın sağkalım avantajı göstermesiyle bu du-
rum değişmektedir. Bu nedenle mide kanserli hastalarda HER 2 ekspresyon 
oranını bilmek önemlidir. Bu çalışmada immünhistokimya ile mide kanser-
li hastalarda HER 2 ekspresyon oranı araştırılmıştır. Gereç ve Yöntem: Antal-
ya Eğitim ve Araştırma Hastane’sinde 2008-2011yılları arasında tanı konu-
lan 50 mide kanserli hasta çalışmaya alındı. Bulgular: Mide kanserli 50 has-
tanın doku örneklerinde HER 2 ekspresyonu, 25’inde (% 50) 0 olarak, 11’inde 
(%22.7) 1, 7’sinde (%14) 2, 7’sinde (%14) 3 olarak skorlandı. Pozitif oranı yak-
laşık % 14 (7/50) idi. Her 2 ekspresyon durumu TNM evresi, lenf nodu durumu, 
uzak metastaz ve yaş ile korele değildi. (p:0.344, p:0.315, p:0.181, p:0.96) Her 
2 ekspresyon durumu cinsiyet ile korele idi. (p:0.041) HER-2 pozitif olan has-
taların tümü erkekti. Tartışma: Çalışmamızda sadece IHC yöntemi kullanılmış 
ve 2 pozitif olan hastalar HER 2 ekspresyonu negatif olarak kabul edilmiştir. 
Meme kanserinden 2 pozitif hastaların bir kısmında FISH yöntemi ile HER 2 
ekspresyonun olduğu bilinmektedir. Bu nedenle HER 2 ekspresyon oranı sap-
tadığımız değerden farklı olabilir.
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Abstract
Aim: Even though gastric cancer incidence decline in many countries, it is still 
among the mostly witnessed cancers in the world. Gastric cancer is a biologi-
cally heterogeneous disease with many genetic and epigenetic variations. 
Despite this heterogeneity of the illness, patients in same stages received 
similar treatments. This changes as transtuzumab shows survival advan-
tages in patients with metastatic gastric cancer. Therefore it is important 
to know the rate of HER 2 expression in patients with gastric cancer. In this 
study, we examined the rate of HER 2 expression in patients with gastric 
cancer by immunohistochemical method. Material and Method: A total of 50 
patients with gastric adenocarcinoma who underwent diagnosed at Antalya 
Education and Research Hospital from 2008 to 2011 were enrolled in this 
study. Results: HER 2 expression of the 50 gastric carcinoma in tissue sam-
ples, 25 (50%) were scored as 0, 11 (22%) as 1, 7 (14%) as 2, and 7 (14%) 
as 3. The positive rate was approximately 14% (7/50). The HER-2 status was 
not correlated with the TNM stage, lymph node status, distant metastasis 
and age ( p:0.344, p:0.315, p:0.181, p:0.96). The HER-2 status was correlated 
with sex (p:0.041). All of the HER-2 positive patients were male. Discussion: 
In our study only IHC method was performed and patients who had a score 
of 2+ were considered to have negative HER 2 expression. It is known that 
some of the patients with breast cancer with a score of 2+ established HER 2 
expression by FISH method. Therefore, we think that HER 2 expression ratio 
may differ from the values we have obtained.
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Introductıon
Even though gastric cancer incidens decline in many countries, 
it is still among the mostly witnessed cancers in the world [1]. 
The disease demonstrates a fast progression upon diagnosis. 
Despite  the  developments  in  diagnosis  and  treatment  tech-
niques and the use of post-surgery adjuvant treatment combi-
nations in local diseases, the disease may still progress [2]. Gas-
tric cancer is a biologically heterogeneous disease with many 
genetic and epigenetic variations. Despite this heterogeneity of 
the illness, patients in same stages received similar treatments. 
This changes as transtuzumab shows survival advantages in pa-
tients with metastatic gastric cancer [3]. Treatment choice is 
considered according to the biology of the disease.
Prognosis of the disease can be estimated by particularly clini-
cal and laboratory parameters that are determined during the 
diagnosis. Determination of the mechanisms playing a part in 
oncogenesis in patients can bring forward the treatments to-
wards the target. Laboratory parameters can be used for the 
determination of treatment intensity and type to be applied to 
patients.
The  HER2  (ERBB2)  is  a  transmembrane  protein  of  185kD 
weight having a tyrosine kinase activity. It is a member of the 
epidermal growth factor receptor family and is synthesized by 
cerb-B2 which is a proto-oncogene . Activation of HER2 recep-
tors leads to the , the activation of cellular signal transduction 
systems, resulting in the cellular transformation and cell pro-
liferation events associated with cancer . Overexpression and 
gene amplification of HER2 have been detected in the develop-
ment and progression of many cancers and studied in breast 
cancer more [4;5]. HER2 amplification is observed in 15–25% of 
all breast cancer cases [6;7]. Rate of HER2 expression in gastric 
cancer shows a wide variety in literature. By immunohistochem-
ical method expression rate was found as %6.8-%34, and %7.1-
%42.6 by Fluorescence in situ hybridization (FISH) method [8]. 
In  first  step  of  the  treatment  of  metastatic  gastric  cancer 
therapies  targeting  HER2  are  used  in  daily  clinical  practice. 
Therefore it is mportant to know the rate of HER2 expression 
in patients with gastric cancer. In this study we examined the 
rate of HER2 expression in patients with gastric cancer, by im-
munohistochemical method.
Material and Method
The Patient Group
A total of 50 patients with gastric adenocarcinoma who un-
derwent diagnosed at Antalya Education and Research Hospital 
from 2008 to 2011 were enrolled in this study. By retrospective 
analysis of patients’ data, stage of the disease and clinicopath-
ological information were obtained. Patients whose treatment 
were started in an other hospital and continued in our hospital 
were not included in this study.
Immunohistochemical studies
Tumor samples obtained right after the surgery or endoscopy 
were fixed in 10% formaldehyde. After fixation, tumor samples 
were embeded in paraffin. Then, histologic sections with a 4 µm 
thickness were obtained from paraffin blocks and were initially 
stained with hemotoxylin- eosine for assessment. 
The histologic sections were de-paraffinized in incubators at 
60°C for one hour. Afterwards, they were kept in xylene for 10 
minutes and in 100% alcohol for 5 minutes and then washed in 
water. Slides were kept in solution buffered with 10% citrate 
solution in microwave at maximum power (800 watts) for 15 
minutes. Then the power was decreased to the half and they 
were kept in the microwave for another 20 minutes. Slides tak-
en out of the microwave were kept in room temperature for 20 
minutes. Endogenous peroxidase activity was removed by being 
kept in 3% hydrogen peroxide for 20 minutes. Slides washed in 
distilled water were treated with 3x5 PBS and protein blockage 
was dripped on them. Five minutes later, Her-2 antibodies were 
dripped on the slides without washing off the blockage. After 
being kept in primer antibody for 30 minutes, they were tak-
en into PBS and washed for 5 minutes. Afterwards, they were 
treated with biotinylated secondary antibody for 20 minutes and 
washed in PBS for 5 minutes. They were kept with peroxidase 
conjugate antibody for 20 minutes. Then they were washed in 
PBS for 5 minutes. They were kept in chromogenous (DAB) for 5 
minutes. Slides washed under tap water were adversely stained 
with haematoxylene. They were dehydrated, dried and mounted 
with entellane.
For the staining of the samples Her-2, lyophilized monoclonal 
mouse antibody (clone e2-4401+ 3B5, 1:600, Thermo Science, 
Fremont, USA) were used.
Immunohistochemical Scoring
Expression of HER 2 in tumor cells was evaluated by a patholo-
gist unaware of the clinical information of the patients, under 
an  olympus  CX41  microscope.  İmmunohistochemical  scor-
ing was made according to the scoring system suggested by 
Hofmann et.al as “Consensus panel recommendations on Her2 
scoring for gastric cancer” [9]. Ccases with a 2+/equivocal score 
were accepted as negative since we were not able to apply FISH 
testing.
Statistical analyses 
Statistical analyses were performed using the SPSS software 
version 15. TNM stage, lymph node status, distant metasta-
sis and being over or under 60 years of old were analysed by 
crossing tables in Her2 positive and negative groups. The Chi-
square test or Fishger’s exact test, where appropriate, was used 
to compare these proportions in different groups. The P-values 
less than 0.05 were considered to be statistically significant.
Results
This study involved a total of 50 patients consisting of 17 (34%) 
females and 33 (66%). The mean age of the patients was found 
as 62±10,7. The most commonly observed complaint was ab-
dominal pain determined in 15 (30%) of the patients and loss 
of weight and dysorexia followed with a decrease in frequency. 
It was determined that in 19 (38%) of the patients diagnosis of 
metastatic disease was made by biopsy and imaging methods 
and the rest of the patients underwent surgery. Twelve (24%) of 
the patients had a liver metastasis, liver was considered as the 
most frequent location for metastasis. Peritoneal metastasis 
was observed in 5 patients whereas 4 (8%) of the patients had 
a synchronous metastasis of liver and periton.
In 64% of the patients ECOG score was determined as 0 and 
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the rest of the patients established an ECOG score of 1. When 
grouped according to stage ; 3 patients (6%) were in stage I, 
7 patients (14%) were in stage II , 11 patients (22%) were in 
stage III and 24 (48%) patients were in stage IV.
HER-2 protein status in 50 gastric carcinoma tissue samples 
was determined with immunohistochemical staining. Of the 50 
gastric carcinoma tissue samples, 25 (50%) were scored as 0, 
11 (22%) as 1, 7 (14%) as 2, and 7 (14%) as 3 (Figure 1-4). The 
positive rate was approximately 14% (7/50). The HER-2 status 
was not correlated with the TNM stage, lymph node status, dis-
tant metastasis and age ( p:0,344, p:0,315, p:0,181, p:0,96). The 
HER-2 status was correlated with sex (p:0,041). All of the Her-2 
positive patients were male (Table 2).
Discussion
Gastric carcinoma is a disease entity with aggressive progres-
sion, exhibiting differences in epidiomiologic and clinical profile 
worldwide. It accounts for approximately 8% of all new cancer 
cases [10]. It occupies the second place as the cause of death 
by cancer [11]. In Turkey, it is the second most-frequently seen 
form of cancer in men, and the third most-frequently seen in 
women [12].
In this study, we have identified the HER2 expression ratio in 
metastatic gastric cancer as 18.8% by IHC. Yano et al. found 
this ratio as 27% using FISH method in 200 Japanese patients 
who underwent surgery for gastric tumor [13]. Tanner et al. 
identified HER2 amplification in 12% of 131 cases of gastric 
adenocarcinoma using CISH method, and in 24% of 100 cases 
with gastroesophageal junction tumor [14].
In the widest range of study on HER2 expression, 3883 patients 
with advanced stage gastric cancer were evaluated and HER2 
positivity was found as 22.9%. In this study, there was not any 
difference  between  European  and  Asian  countries.  Intestinal 
type of HER2 positivity was found at a higher ratio than the 
diffuse/mixed type. In gastroesophageal junction tumors, HER2 
positivity was identified at a higher rate than the gastric tumors 
[15].
Determination of prognostic factors in gastric cancer has an 
important role in estimating the survival of the patients and 
determining the treatment method. In many studies the depth 
of invasion and lymph node metastasis of the tumor are dem-
onstrated to be important prognostic factors [16;17]. Param-
eters such as the depth of invasion of the tumour (T), local 
lymph node metastasis (N) and distant metastasis (M) are used 
in TNM staging. The studies show that patients in the same 
pathological stage may have different prognosis. Many biologi-
cal reagents are observed in order to determine these different 
prognostic groups [18;19].
Our study shows that, HER-2 status was not correlated with 
the TNM stage, lymph node status, distant metastasis and age. 
Yan et al found the rate of Her-2 expression as 15.2% in their 
study, similiar to the rate we found. They found a significant cor-
relation between Her-2 expression and TNM satge, lymph node 
metastasis and distant metastasis in their study. In our study 
we found a relation betwwen sex and Her-2 expression while 
no such relation was found in the study of Yan et. Al [20]. Our 
study consisted of 17 female patients, therefore we think that 
the reason of this difference may be the small number of the 
patients of our study. The correlation between the Her2 status 
and TNM stage, lymph node and distant metastasis had been 
searched in many studies. Different results were obtained in 
these studies and in some of them a significant correlation was 
found whereas some established no relationship [20-22].
In our study only IHC method was performed and patients who 
Figure  1.  No  staining  (score  0),  HER2 
x200
Figure  2.  Weak  and  incomplete  mem-
brane staining of tumor cells (score 1+), 
HER2 x200
Figure  3.  Complete  membrane  staining 
at least 10% of tumor cells, nonuniform 
and weak intensity (score 2+), HER2 x200
Figure  4.  Uniform  intense  mebrane 
staining of >30% of tumor cells (score 
3+), HER2 x400
Table 1. General characteristics of patients
Mean,Standard Deviation Median
Age 62±10,7 62,5
AST (U/L) 21,5±8 20
ALT (U/L) 22,5±15,6 18
ALP (U/L) 181,8±28.1 93
LDH (U/L) 218,3±70,9 190
WBC (103/mm3) 5.6±0,8 5.6
HGB (g/dl) 9,5±1.4 10.9
PLT(103/mm3) 329,3±47.1 320
Table 2. Patient groups according to Her-2 status
Her2 Negative Her 2 Pozitive P Value
Gender
 Kadın 17 (39.5%) 0 p:0.041
 Erkek 26 (60.5%) 7(100%)
 Age 63±10.4 61±13.2 p:0.96
Stage
 Stage 1 3 (7%) 1(14.3%) p:0.344
 Stage 2 7 (16.3%)  0
 Stage 3 13 (30.2%) 1(14.3%)
 Stage 4 20 (46.5%) 4(71.4%)
Lymph Node Status  p:0.315
 Metastatic  35 (%81.4) 7 (100%)
 Nonmetastatic 8 (%18.6) 0
Distant Metastasis  p:0.181
 Negative  23 (53.5%) 2 (28.6%)
 Pozitive 20 (46.5%) 5 (71.4 %)
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had a score of 2+ were considered to have negative HER2 ex-
pression. It is known that some of the patients with breast can-
cer with a score of 2+ established HER2 expression by FISH 
method. Therefore, we think that HER2 expression ratio may 
differ from the values we have obtained.
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